BRAF and cancer: E6201 is a novel MEK1/2 inhibitor which inhibits selected cancer-specific kinases that is currently in clinical trials for solid tumours and, as a result of the data presented herein, is undergoing Phase I expansion in BRAF-mutant malignancies (NCT00794781, ClinicalTrials.gov).